Elabela: The Peptide Powering Cardiovascular Resilience

Imagine a tiny, naturally occurring peptide acting as a molecular shield, protecting our vital organs from some of the most pervasive threats to health. That's the promise emerging from exciting research into Elabela, a peptide increasingly recognized for its significant role in cardiovascular and renal function. From battling the hardening of arteries to defending the heart against the ravages of high blood pressure, Elabela is making waves in the scientific community, hinting at a future where our bodies' own molecules could offer novel avenues for treatment.

What is Elabela

Elabela (also known as Apela or Toddler) is a peptide that has garnered attention as a relatively recent discovery, identified in the 21st century (PMID 34067710). For a long time, the apelin receptor (APJ) was thought to have only one endogenous ligand, Apelin. However, Elabela was found to be a new polypeptide that can also act through APJ, sharing some functional similarities with Apelin (PMID 34718064, PMID 37433415). It's primarily expressed in cardiac microvascular endothelial cells (CMVECs) and renal tubules (PMID 35122997, PMID 37351176). This peptide is considered a broad regulator of physiology, opposing the actions of systems like the renin-angiotensin and vasopressin systems (PMID 37956047).

Why researchers are excited

Researchers are highly enthusiastic about Elabela's potential due to its widespread protective effects, particularly within the cardiovascular and renal systems. Its ability to promote endothelium-dependent vasodilation, improve heart contractility (inotropy), lower blood pressure, and encourage new blood vessel formation (angiogenesis) points to a versatile agent with broad therapeutic promise (PMID 37956047, PMID 37433415). Beyond these general benefits, specific studies highlight its protective roles against arrhythmias, thrombosis, and its anti-inflammatory and anti-fibrotic actions, making it a compelling target for addressing a range of cardiovascular, kidney, and metabolic diseases (PMID 37956047). The discovery of Elabela as a crucial player in embryonic cardiovascular system formation and early placental development further underscores its fundamental importance (PMID 30910349, PMID 34718064).

What the studies found

Elabela has demonstrated remarkable protective effects across various *in vivo* and *in vitro* models, primarily in cardiovascular and kidney health.

| Study | Model | Key finding | PMID | |---|---|---|---| | Elabela alleviates cuproptosis and vascular calcification | VitD3-overloaded mice; primary rat VSMCs | Effectively hindered arterial calcification, reduced copper levels, and prevented mitochondrial dysfunction (in VSMCs) | 39567863 | | Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice | Angiotensin II-infused mice; CMVECs, cardiac fibroblasts, cardiomyocytes (in vitro) | Prevented pathological myocardial remodeling, dysfunction, and ultrastructural injury; alleviated iron accumulation and lipid peroxidation | 35122997 | | Tubular Elabela-APJ axis attenuates ischemia-reperfusion induced acute kidney injury | Renal tubule specific ELA knockout mice; injured mice treated with ELA32 peptide | Attenuated acute kidney injury and its progression to chronic kidney disease by protecting renal microcirculation | 37351176 |

In one study, Elabela administration effectively **hindered the progression of arterial calcification and copper-dependent cell death (cuproptosis)** in vitamin D3-overloaded mice (PMID 39567863). This was accompanied by a striking reversal of high phosphate-induced FDX1 expression and intracellular copper ion levels in primary rat vascular smooth muscle cells (VSMCs) (PMID 39567863). It also significantly suppressed osteogenic differentiation and calcium deposition in these cells (PMID 39567863). Moreover, Elabela exhibited remarkable abilities to prevent mitochondrial dysfunctions in primary rat VSMCs by maintaining mitochondrial membrane potential, inhibiting mitochondrial division, reducing mitochondrial reactive oxygen species production, and increasing ATP levels (PMID 39567863). Elabela also mitigated cellular senescence and the production of pro-inflammatory cytokines like IL-1α, IL-1β, IL-6, IL-18, and TNF-α (PMID 39567863).

Another study demonstrated Elabela's significant impact in a mouse model of hypertension. Administration of Elabela **prevented angiotensin II-mediated pathological myocardial remodeling, dysfunction, and ultrastructural injury** in hypertensive mice (PMID 35122997). It strikingly alleviated angiotensin II-induced increases in iron levels and lipid peroxidation in these mice (PMID 35122997). In cultured cardiac microvascular endothelial cells (CMVECs), Elabela rescued angiotensin II-induced increases in cellular ferroptosis, proliferation, inflammation, and superoxide production (PMID 35122997).

In the context of kidney health, an endogenous tubular Elabela-APJ axis was found to **attenuate ischemia-reperfusion induced acute kidney injury (AKI) and prevent its progression to chronic kidney disease (CKD)** in mice (PMID 37351176). This protective effect was linked to Elabela's role in regulating renal microvascular blood flow (PMID 37351176).

How it's thought to work

Elabela's actions are primarily mediated through its binding to the APJ receptor (PMID 37351176, PMID 37433415). This interaction triggers a cascade of intracellular signaling pathways that lead to its observed beneficial effects.

For example, in alleviating vascular calcification and cuproptosis, Elabela is thought to work by **activating the peroxisome proliferator-activated receptor-γ (PPAR-γ)/FDX1 signaling pathway** (PMID 39567863). Elabela upregulated the protein levels of PPAR-γ in vitamin D3-overloaded mice (PMID 39567863). Blocking PPAR-γ or the efflux of intracellular copper abolished Elabela's protective effects, highlighting the importance of this pathway (PMID 39567863).

In hypertensive mice, Elabela antagonized angiotensin II-mediated adverse effects by **modulating the IL-6/STAT3/GPX4 signaling** (PMID 35122997). It suppressed cardiac interleukin-6 (IL-6)/STAT3 signaling and activated the xCT/glutathione peroxidase (GPX4) signaling pathway, thereby reducing iron levels and lipid peroxidation (PMID 35122997). In cultured CMVECs, the protective effects of Elabela were blocked by co-treatment with rhIL-6 (PMID 35122997).

In the kidneys, the tubular Elabela-APJ axis regulates renal microvascular blood flow (PMID 37351176). RNA-sequencing analysis suggested that Elabela's protective role involves altering the levels of blood flow regulators such as the arginine metabolizing enzyme arginase 2 (ARG2) and prostaglandin E2 (PGE2) metabolizing enzymes (PMID 37351176).

Overall, Elabela promotes cell proliferation and is essential for heart development (PMID 34718064, PMID 37433415). The apelin system, including Elabela, promotes endothelium-dependent vasodilation and inotropy, lowers blood pressure, and promotes angiogenesis (PMID 37956047).

The catch: what we still don't know

While the findings on Elabela are undeniably exciting, the research is still in its early stages. Many of the impressive results reported thus far come from **animal models (mice and rats) and *in vitro* (cell culture) studies**. The effects seen in these controlled environments do not always translate directly to humans. For instance, while Elabela-deficient mice display features consistent with preeclampsia, current clinical studies showed no difference in circulating Elabela levels between preeclampsia and control patients, suggesting its role in human preeclampsia development may not be straightforward (PMID 30910349).

Furthermore, while peripheral administration of Elabela exhibits antihypertensive, vascular-protective, and cardioprotective effects, central administration in some instances elevated blood pressure and caused cardiovascular remodeling, indicating the importance of delivery route and tissue specificity (PMID 37433415). More research is needed to fully understand Elabela's complex mechanisms, optimal delivery, and potential interactions before it can be considered for human therapeutic applications. The full spectrum of its physiological and pathological roles, especially in humans, remains to be comprehensively mapped.

Keep exploring

Elabela is a prime example of the incredible potential held within our own biological systems. As research continues to unfold, understanding peptides like Elabela could unlock new strategies for tackling some of the most pressing health challenges. Dive deeper into the fascinating world of peptides by browsing our A–Z protocols and comparing compounds. Share this article with fellow science enthusiasts and help spread the word about these groundbreaking discoveries!

Sources

* Elabela alleviates cuproptosis and vascular calcification in vitaminD3- overloaded mice via regulation of the PPAR-γ /FDX1 signaling. Molecular medicine (Cambridge, Mass.) 2024. https://pubmed.ncbi.nlm.nih.gov/39567863/ * Targeting the apelin system for the treatment of cardiovascular diseases. Cardiovascular research 2023. https://pubmed.ncbi.nlm.nih.gov/37956047/ * Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling. Free radical biology & medicine 2022. https://pubmed.ncbi.nlm.ih.gov/35122997/ * Tubular Elabela-APJ axis attenuates ischemia-reperfusion induced acute kidney injury and the following AKI-CKD transition by protecting renal microcirculation. Theranostics 2023. https://pubmed.ncbi.nlm.nih.gov/37351176/ * The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Adipose Tissue Functions. Genes 2021. https://pubmed.ncbi.nlm.nih.gov/34067710/ * Elabela and Apelin actions in healthy and pathological pregnancies. Cytokine & growth factor reviews 2019. https://pubmed.ncbi.nlm.nih.gov/30910349/ * Effects and signaling pathways of Elabela in the cardiovascular system. Peptides 2022. https://pubmed.ncbi.nlm.nih.gov/34718064/ * Cardiovascular aspects of ELABELA: A potential diagnostic biomarker and therapeutic target. Vascular pharmacology 2023. https://pubmed.ncbi.nlm.nih.gov/37433415/